Underdosing in Patients With Cancer and Obesity: A Thing of the Past?
New guidelines recommend using the full approved doses of immunotherapy and targeted therapies for patients with cancer and obesity.
Multiple Myeloma
MULTIPLE MYELOMA ADVISOR
FEATURED CONTENT
-
-
Age and Race May Determine Whether Cancer Patients Access Their Electronic Health Records
Black cancer patients were 44% less likely than White patients to enroll in a portal that provides access to electronic health records. -
Deeper Dives Into the Bone Marrow Microenvironment of Myeloma Cells Provide New Insights Into Novel Therapies and Disease Biology
The immune cells in the microenvironment can reign in myeloma cells but become suppressed and dysregulated during disease progression. -
Recommendations From FDA-AACR Workshop to Increase African American Representation in Multiple Myeloma Clinical Trials
A workshop was convened by the US Food and Drug Administration and the American Association for Cancer Research to create recommendations for trial design and later stages of drug development in multiple myeloma. -
Therapeutic Approaches to Multiple Myeloma: An Interview With Ajai Chari, MD
Ajai Chari, MD, of Mount Sinai Hospital in New York City, provides his perspective on the current state of care in multiple myeloma.
MULTIPLE MYELOMA NEWS
Mobile Wearable Devices Show Some Sleep Disturbances During Multiple Myeloma Treatment
Iberdomide-Based Regimens Show Promise in Relapsed/Refractory Multiple Myeloma
Long-Term Follow-Up Data Support Adding Daratumumab to Lenalidomide/Dexamethasone in Transplant-Ineligible MM
Continued Benefit Observed With Isatuximab Plus Pomalidomide and Dexamethasone in Multiple Myeloma
BCVA Changes and Ocular Symptoms May Aid Belamaf Dosing in Relapsed/Refractory Multiple Myeloma
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Multiple Myeloma
Loading... 
Loading...